Newswire, Sept. 27, 2006 BioCryst Pharmaceuticals announced today that it would present positive data from preclinical testing of its neuraminidase inhibitor, peramivir, at the 46th Annual Interscience Conference in San Francisco on Saturday. The research to be presented was performed at the University of Texas Medical Branch at Galveston and was funded by the National Institute of Allergy and Infectious Diseases. The presentation describes the studies in the mouse and ferret models of influenza caused by a strain of avian influenza virus (H5N1) that caused fatal human illness.